Hyperfine Secures $6 Million Funding to Enhance Swoop® Diagnostic Imaging Capabilities

Hyperfine Secures Funding to Enhance Diagnostic Imaging Capabilities

Hyperfine, Inc., a leader in health technology renowned for its Swoop® system, announces a definitive agreement for a registered direct offering aimed at raising approximately $6 million. The company plans to issue 4,511,278 shares of its Class A common stock, accompanied by warrants for an equal number of shares, at a price of $1.33 each. This strategic move is anticipated to close on February 12, 2025, subject to standard closing conditions. Lake Street Capital Markets acts as the exclusive placement agent for this transaction, which is conducted under an effective shelf registration statement with the U.S. Securities and Exchange Commission (SEC).

The proceeds from this offering are designated for working capital and general corporate purposes. Hyperfine intends to bolster its commercial, manufacturing, and research and development efforts, aligning with its mission to transform patient care through accessible and clinically relevant diagnostic imaging. The Swoop® system, an FDA-cleared, portable, ultra-low-field magnetic resonance imaging (MRI) device, exemplifies the company's commitment to advancing healthcare technologies that enhance diagnostic capabilities, particularly in settings where traditional imaging methods may be impractical.

Hyperfine's focus on accessibility is particularly significant in the current healthcare landscape, where the demand for portable and efficient diagnostic tools continues to grow. By leveraging the funds raised from this offering, the company aims to accelerate the development of its innovative technologies, ensuring that high-quality brain imaging becomes available in diverse healthcare environments. This initiative underscores Hyperfine's dedication to improving patient outcomes through cutting-edge imaging solutions that can be deployed in various clinical scenarios.

In addition to the funding news, Hyperfine emphasizes its commitment to transforming global patient care. The company views its Swoop® system as a pivotal element in expanding access to critical diagnostic services, especially in under-resourced areas. By continuing to invest in research and development, Hyperfine aims to enhance the capabilities of its imaging technologies and further solidify its position in the health technology sector.

As the company progresses, it remains focused on its core mission of improving healthcare delivery through innovation. The upcoming funding will play a crucial role in advancing its efforts and expanding the reach of its groundbreaking imaging solutions.